Precision Medicine in Colorectal Cancer: Harnessing the Power of MRD Surveillance and Emerging Guidelines will take place on November 13, 2026, as a live virtual webinar hosted by OncoDaily in partnership with Natera.

The session will focus on the growing role of circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing in the evolving management of colorectal cancer.

Led by Dr. Rob Lentz, the webinar will explore how longitudinal ctDNA surveillance can inform post-operative monitoring and adjuvant treatment decisions. Participants will review emerging clinical evidence, updated consensus guidelines, and real-world data on serial ctDNA monitoring, including its potential to identify recurrence earlier than standard imaging.

The discussion will also examine practical decision-making frameworks around treatment escalation and de-escalation in the adjuvant setting, as well as emerging neoadjuvant immunotherapy combinations. The session is designed to provide clinicians with an understanding of how personalized molecular monitoring is influencing the future of colorectal cancer care.